Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study

J Eur Acad Dermatol Venereol. 2014 Aug;28(8):1127-9. doi: 10.1111/jdv.12343. Epub 2013 Dec 13.

Authors

B Sigurgeirsson¹, L Kircik, O Nemoto, I Mikazans, S Haemmerle, H J Thurston, C Papavassilis, H B Richards

Affiliation

¹ Faculty of Medicine, Department of Dermatology, University of Iceland, Reykjavik, Iceland.

PMID: 24330415
DOI: 10.1111/jdv.12343

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Randomized Controlled Trial

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Double-Blind Method
Foot / pathology*
Hand / pathology*
Humans
Placebos
Psoriasis / drug therapy*
Severity of Illness Index

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Placebos
secukinumab